The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial

• Published in: BMJ open diabetes research & care Vol. 3; no. 1; p. e000079
• Main Authors: Soare, Andreea, Del Toro, Rossella, Roncella, Elena, Khazrai, Yeganeh Manon, Angeletti, Silvia, Dugo, Laura, Fallucca, Sara, Fontana, Lucia, Altomare, Maria, Formisano, Valeria, Capata, Francesca, Gesuita, Rosaria, Manfrini, Silvia, Fallucca, Francesco, Pianesi, Mario, Pozzilli, Paolo
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.01.2015; BMJ Publishing Group
• Subjects: s in Diabetes; Inflammatory Markers; Type 2 Diabetes; Insulin Resistance; Dietary Intervention
• ISSN: 2052-4897; 2052-4897
• DOI: 10.1136/bmjdrc-2014-000079

IntroductionCurrent guidelines for the management of type 2 diabetes (T2D) emphasize diet as essential therapy. However, the effect of diet on systemic inflammation remains unclear. We investigated the effects of consuming a macrobiotic Ma-Pi 2 diet versus a standard recommended diet (control diet) on markers of inflammation in patients with T2D.MethodsThis was a post hoc analysis of the MADIAB trial, a 21-day randomized controlled trial conducted in 51 patients (25 males and 26 females) with T2D. Patients were randomized 1:1 to the Ma-Pi 2 macrobiotic diet or a control diet based on dietary guidelines for T2D. Biological antioxidant potential of plasma and circulating levels of high-sensitivity C reactive protein, interleukin-6, tumor necrosis factor-α, and insulin-like growth factor-1 were assessed.ResultsAfter 21 days on the Ma-Pi 2 or control diet, markers of inflammation were reduced in both groups. The antioxidant potential of plasma improved significantly in the Ma-Pi group. A significant reduction in insulin growth factor-1 was observed in the Ma-Pi group versus control group (p<0.001).ConclusionsFindings of this post hoc analysis demonstrated that the Ma-Pi 2 diet is a safe dietary strategy to reduce levels of the markers of insulin resistance and inflammation, compared with baseline values, in the short term. Furthermore, the Ma-Pi 2 diet was superior to the control diet in reducing insulin growth factor-1 and may be beneficial for patients with T2D.Trial registration numberCurrent Controlled Trials ISRCTN10467793.